Eloxx制药
ELOX

Common stock offered 305,590 shares by the company

Eloxx Pharmaceuticals, Inc. announced that its Board of Directors has approved a 1-for-40 reverse stock split of the Company’s common stock.

From March 31, 2022 to June 30, 2022 Vesting of restricted stock units

From December 31, 2021 to March 31, 2022 Vesting of restricted stock units

From December 31, 2020 to December 31, 2021 Exercise of stock options Vesting of restricted stock units Issuance of common stock in connection with merger Issuance of shares upon public offering, net of offering costs

From June 30, 2021 to September 30, 2021 Exercise of stock options Vesting of restricted stock units

From March 31, 2021 to June 30, 2021 Exercise of stock options Vesting of restricted stock units Issuance of common stock in connection with merger Issuance of shares upon public offering

1.Common stock offered by the company 33,333,334 shares of common stock，Under the terms of the Underwriting Agreement, the Company has also granted the Underwriter an option exercisable for 30 days to purchase up to an additional 5,000,000 shares of its common stock at the public offering price, less underwriting discounts and commissions, which was exercised in full. 2.The number of shares of common stock to be outstanding after this offering is based on 40,214,874 shares of common stock outstanding as of March 31, 2021 and the issuance of 7,596,810 shares in connection with the acquisition of Zikani (the “Acquisition”) on April 1, 2021.

From December 31, 2020 To March 31, 2021 Vesting of restricted stock units

From December 31, 2019 to December 31, 2020 Exercise of stock options Vesting of restricted stock units

From June 30, 2020 to September 30, 2020 Exercise of stock options Vesting of restricted stock units

From March 31, 2020 to June 30, 2020 Vesting of restricted stock units

From December 31, 2019 to March 31, 2020 Exercise of stock options Vesting of restricted stock units

from December 31, 2018 to December 31, 2019 Exercise of stock options Issuance of shares upon execution of warrants Issuance of shares upon public offering Issuance of common stock from at-the-market sales agreement Vesting of restricted stock units

from June 30, 2019 to September 30, 2019 Exercise of stock options Vesting of restricted stock units

From March 31, 2019 to June 30, 2019 Exercise of stock options Issuance of shares upon execution of warrants Vesting of restricted shares Issuance of shares upon equity financing, net of $211 issuance costs

from December 31, 2018 to March 31, 2019 Exercise of stock options Vesting of restricted shares Issuance of shares from at-the-market sales agreement

From December 31, 2017 to December 31, 2018 Issuance of shares upon execution of warrants Repurchase of common stock Vesting of restricted shares

From December 31, 2017 to September 30, 2018 Issuance of common stock related to share-based compensation Issuance of common stock Techion settlement Issuance of shares upon execution of warrants Issuance of shares upon public offering Repurchase of Common Stock

From December 31, 2017 to June 30, 2018 Issuance of common stock related to share-based compensation Issuance of common stock Techion settlement Issuance of shares upon execution of warrants Issuance of shares upon public offering Repurchase of Common Stock

1.Common stock offered 5,130,000 shares 2.The number of shares of our common stock to be outstanding after this offering is based on 27,527,738 shares of our common stock outstanding as of December 31, 2017

from June 30, 2008 to June 30, 2009 Convertible notes converted into common stock during the year ended June 30, 2009, net of deferred financing costs Issuance of common stock in lieu of cash payment for interest during the year ended June 30, 2009 Warrants exercised during the year ended June 30, 2009 at an exercise price of $0.01 Issuance of common stock in connection with short-term incentive program during the year ended June 30, 2009

from June 30, 2007 to June 30, 2008 Convertible notes converted into common stock during the year ended June 30, 2008, net of deferred financing costs Issuance of common stock in lieu of cash payment for interest during the year ended June 30, 2008

from June 30, 2006 to June 30, 2007 Issuance of common stock and warrants for cash on October 10, 2006 at $1.135 per unit Warrants exercised during the year ended June 30, 2007 at an exercise price of $0.01

from June 30, 2005 to June 30, 2006 Warrants exercised during the year ended June 30, 2006 at an exercise price of $0.01

from June 30,2004 to June 30,2005 Issuance of common stock and warrants for cash on May 9, 2005 at $2.11 per unit Options and warrants exercised during the year ended June 30, 2005 at exercise prices ranging from $1.50 - $3.25

from June 30, 2003 to June 30, 2004 Issuance of common stock and warrants for cash from January 15, 2004 through February 12, 2004 at $2.37 per unit Options and warrants exercised during the year ended June 30, 2004 at exercise prices ranging from $1.00 - $3.25

from June 30, 2001 to June 30, 2002 Issuance of common stock and warrants for cash on November 30,2001 at $1.75 per unit Issuance of common stock and warrants associated with bridge loan conversion on December 3, 2001 Issuance of common stock and warrants for cash on December 26,2001 at $1.75 per unit Issuance of common stock and warrants for cash on January 16,2002 at $1.75 per unit Issuance of common stock and warrants for cash on January 23,2002 at $1.75 per unit Issuance of common stock and warrants for cash on February 21,2002 at $1.75 per unit Issuance of common stock and warrants for cash on February 27,2002 at $1.75 per unit Issuance of common stock and warrants for cash on March 12,2002 at $1.75 per unit Issuance of common stock and warrants for cash on March 15,2002 at $1.75 per unit Issuance of common stock and warrants for cash on April 12,2002 at $1.75 per unit Issuance of common stock and warrants for cash on April 17,2002 at $1.75 per unit